New studies suggest that Nadecenemab , a experimental monoclonal antibody , has the potential to reduce the development of mild Alzheimer's . This treatment targets removing amyloid plaques within https://declanqubf931973.blog-gold.com/57789827/donanemab-an-emerging-novel-alzheimer-s-treatment